Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.68 |
| ▸ | GAA | P10253 | 3/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | OXTR | P30559 | 1/20 | 0.48 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.47 |
| ▸ | FEN1 | P39748 | 1/20 | 0.47 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | CFTR | P13569 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12427049 | 0.97 | KDM4E (0.64) | KDM4EGAAGLAALDH1A1SMN1; SMN2 | |
| SCHEMBL1547993 | 0.84 | KDM4E (0.55) | KDM4EGAAGLAALDH1A1SMN1; SMN2 | |
| SCHEMBL4433382 | 0.83 | ALDH1A1 (0.67) | KDM4EGAAGLAALDH1A1SMN1; SMN2 | |
| SCHEMBL4074369 | 0.83 | KDM4E (0.50) | KDM4EGAAGLAALDH1A1SMN1; SMN2 | |
| SCHEMBL4074628 | 0.81 | KDM4E (1.00) | KDM4EGAAALDH1A1SMN1; SMN2RXFP1 | |
| SCHEMBL12427048 | 0.81 | CFTR (0.54) | KDM4EGAAGLAALDH1A1SMN1; SMN2 | |
| SCHEMBL4429564 | 0.81 | MDM2 (0.68) | KDM4EGAAALDH1A1SMN1; SMN2RXFP1 | |
| SCHEMBL12427050 | 0.80 | CFTR (0.52) | KDM4EGAAGLAALDH1A1SMN1; SMN2 | |
| SCHEMBL17266872 | 0.79 | SLC6A3 (0.47) | KDM4EGAAALDH1A1SMN1; SMN2RXFP1 | |
| SCHEMBL4429820 | 0.78 | KDM4E (0.93) | KDM4EGAAALDH1A1SMN1; SMN2RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023062575-A1 | CYCLIC VINYL SULFONE COMPOUNDS AS WRN INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
| EP-3814330-A1 | IMMUNOMODULATORY COMPOUNDS | Dana-Farber Cancer Institute, Inc. (US) | 2021-05-05 | — | — | EP | disclosed |
| EP-3436461-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | Incyte Corporation (US) | 2019-02-06 | — | — | EP | disclosed |
| WO-2017172596-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORPORATION (US) | 2017-10-05 | — | — | WO | disclosed |
| US-8461183-B2 | PPAR agonist compounds, preparation and uses | GENFIT (FR) | 2013-06-11 | — | — | US | disclosed |
| EP-2310371-B1 | PPAR AGONIST COMPOUNDS AND PREPARATION AND USES THEREOF FOR TREATING DIABETES AND/OR DYSLIPIDEMIA | GENFIT (FR) | 2013-05-15 | — | — | EP | disclosed |
| US-20110195993-A1 | PPAR AGONIST COMPOUNDS, PREPARATION AND USES | GENFIT (FR) | 2011-08-11 | — | — | US | disclosed |
| EP-2125739-A1 | MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | ENCYSIVE PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | ENCYSIVE PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | ENCYSIVE PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| WO-2008079371-A1 | MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008079371-A1 | MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| EP-1742948-A2 | BICYCLIC HETEROCYCLES AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2007-01-17 | — | — | EP | disclosed |
| EP-1737451-A2 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005117867-A2 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005116028-A2 | BICYCLIC HETEROCYCLES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195993-A1 | PPAR AGONIST COMPOUNDS, PREPARATION AND USES | PPARD, PPARA, PPARG | KDM4E 3040/4885GAA 1485/4885GLA 1394/4885 |
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | C3AR1, C5, C5AR1 | KDM4E 2635/4885GAA 4404/4885GLA 1934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.